Tokyo, Japan and Cambridge, UK, 22 December 2020 – Sosei Group Corporation (“the Company”; TSE: 4565), a world leader in GPCR-focused structure-based drug design and development, and Captor Therapeutics SA (“Captor”; Wroclaw, Poland and Allschwil, Switzerland), a European leader in targeted protein degradation, have entered a strategic technology collaboration focused on the discovery and development of novel small molecules that target the degradation of disease-associated G protein-coupled receptors (GPCRs).
News
As we look towards 2021 and beyond, Deloitte has unveiled ten predictions on how patients, healthcare and life science companies and their staff might behave and operate in five years’ time, based on today’s evidence.
• Advances in AI-enabled robotics, cognitive automation, digitalisation and life-long learning will help task shifting and role-enrichment, changing the who, what, and where of work.
Research Triangle Park, NC, USA and Cambridge, UK, 18 December 2020 – Inivata, a leader in liquid biopsy, today announces its participation in a major research collaboration to investigate integrated diagnostics for the early detection of lung cancer with the aim of increasing survival rates, alongside improving the efficiency of testing in people at high risk of cancer in the NHS. The program’s goal is to streamline the process of detecting cancers and reduce the NHS resources that are needed in order to find each new case.
Cambridge, UK, 17 December 2020 Mogrify Limited (Mogrify®), a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, today announced it had secured the assignment of the foundational intellectual property (IP) underpinning its core direct cell conversion technology (MOGRIFY® V1) and extended the method to allow for the inclusion of new sources of data and more accurate transcription factor predictions (MOGRIFY V2).
Clinical studies are complex, so involving biostatisticians early in the product development has major benefits for the quality of data collected and how it can be used.
The main goal of any clinical study is to make the best-informed decision based on data and sophisticated biostatistical analyses. In too many cases there are far too many data points gathered. As biostatistics teams are the ones who handle this vast data, their guidance is crucial at all stages of product development planning.
ARESTAT™ formulated product progressing into clinical trial
Cambridge, UK., 17th December 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™. This is the first license under a multi-product development agreement between Inhibrx and Arecor.
AMSBIO has published an interview with researchers at Yamaguchi University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Japan, that covers their groundbreaking work to develop cell regeneration therapies for liver cirrhosis.
AT247, a promising candidate in the pursuit for next generation insulins to improve glycemic control
Cambridge, UK, 16 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product candidate.
CAMBRIDGE, UK (Dec 15th, 2020) – Nuclera, the UK-based biotech company developing desktop gene and protein printing technologies, announces that it has been awarded a Knowledge Transfer Partnership (KTP) grant in support of its work with researchers at the University of Southampton.